Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 28c; reaffirms guidance
(Updated - August 9, 2023 9:07 AM EDT)
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.60), $0.28 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $188 million versus the consensus estimate of $140.11 million.
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.